For example, 13–45% of the 100 most down-regulated genes in HAP1 were also deregulated in prostate adenocarcinoma, lung squamous cell carcinoma, and skin cutaneous melanoma when comparing patients with and without the PAPSS2-PTEN locus deletion (Table S12). This evidence concerns the gene HAP1 and prostate adenocarcinoma.